| Clinical data | |
|---|---|
| Trade names | Celontin |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682028 |
| Routes of administration | By mouth (capsules) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic (demethylation and glucuronidation) |
| Metabolites | N-desmethylmethosuximide |
| Elimination half-life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.934 |
| Chemical and physical data | |
| Formula | C12H13NO2 |
| Molar mass | 203.241 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| | |
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)1 and Celontin (United States).2 The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.3
Medical use
The medical use is indicated for the control of absence seizures that are refractory to other drugs.2
References
References
- Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
- Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
- Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.